| Ticker: GSII | 3172A Porter Drive | |
| Exchange: NASDAQ-National Market | Palo Alto, California 94304 | |
| Industry: Manufacturing | (415) 812-9730 |
| Type of Shares: | Common Shares | Filing Date: | 3/27/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 5/10/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $15.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.05 | |
| Offering Amount: | $36,000,000 | Selling: | $0.59 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 12,653,342 |
| Manager | Tier | Phone |
| Cowen & Company | Lead Manager | (212) 495-6000 |
| UBS Securities Inc. | Co-manager | (212) 230-4000 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $2.44 | $3.42 | $1.81 | Assets: | $6.71 |
| Net Income: | -$4.05 | -$5.44 | -$2.94 | Liabilities: | $3.45 |
| EPS: | -$0.40 | -$0.53 | -$0.29 | Equity: | $3.26 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company develops, manufactures and sells balloon dissection systems for minimally invasive surgery. Each of the company's proprietary Spacemaker balloon dissection systems consists of an access and deployment platform and a balloon dissector. By using the company's products, surgeons can access a surgical site in a minimally invasive manner and can rapidly and relatively atraumatically create a working space at the target surgical site where no space previously existed. The company's balloon dissection systems are currently offered in four access and deployment platforms, along with 14 different balloon shapes and sizes, which are specifically designed for various surgical techniques, procedure types and market segments. The company commenced commercial sales of its first product, the Spacemaker I platform for hernia repair, in September 1993 and to date almost all of the company's revenues have been derived from sales of products for this procedure, primarily pursuant to a distribution agreement with United States Surgical Corporation. The company currently sells products in the United States and certain other countries, including the United Kingdom, Germany, and France, for selected applications, including hernia repair, subfacial endoscopic perforator surgery and breast augmentation and reconstruction. |
| Use of Proceeds |
| The proceeds from the offering will be used for sales and marketing activities, research and development, marketing-related clinical evaluations, capital expenditures, expansion of manufacturing and other facilities and for other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.